SARcode Corp., Sunesis deal

SARcode purchased Sunesis' LFA-1 (CD11a-CD18) inhibitor program for $2 million in cash. The program's lead compound is SAR1118, an eye drop formulation of small molecule LFA-1 antagonist in Phase I ...